Plain-English translation of NCT06739759 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing two different medication approaches to help prevent ovarian hyperstimulation syndrome (OHSS)—a potentially serious side effect that can occur during fertility treatment—in women with PCOS (polycystic ovary syndrome). You would receive either an antagonist protocol or a modified agonist protocol with additives. The goal is to find which approach best prevents this complication while still supporting your fertility treatment.
Women with PCOS are at higher risk for developing ovarian hyperstimulation syndrome during fertility treatment, which can cause discomfort and, in severe cases, serious health problems. This trial is trying to find the safest medication approach to prevent this complication.
You likely qualify if…
You likely don't qualify if…
You would be assigned to receive one of two medication protocols as part of your fertility treatment. One group receives an antagonist medication, while the other receives a modified agonist medication with additional support. Your medical team would monitor you throughout your fertility treatment to track how well the medication works and whether you develop any signs of ovarian overstimulation.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Egypt
Sponsor
Aljazeera Hospital
Enrollment target
~300 participants
Started
November 2024
Primary completion
June 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
19 Years – 42 Years
Sex
Female only
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mahmoud Alalfy, MD
Aljazeera Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.